1. ADNI 3 UPDATE
MICHAEL WEINER

2. SUCCESSES AND PROBLEMS
Over 1400 publications from ADNI!!!
Updated ADNI website on LONI
All but a few sites are enrolling
Unfortunately enrollment is slow: especially for MCI, AD , and minorities
Very substantial baseline tau PET, some longitudinal
Availability of AV 1451 has been problematic
Enrollment will continue to at least 900 participants

3. FIXED ADNI DATA SETS The ADNI data base is constantly being updated
As it should be
In the past, we have had requests for “fixed data sets” for various purposes: “challenges”
We now plan to establish a number of fixed data sets
May be identified with specific questions: e.g.
Predicting amyloid status from genetics
Predicting cognitive decline/conversion
Seeking individuals interested in being involved

4. INCREASED INTEREST IN BLOOD TESTS
Polygenic risk scores
Impact of low cost whole genome sequencing
Impact of DNA methylation, telomeres in WBCs
Plasma AB 42/40
Araclon antibody
Recent Bateman MS results
Nakamura MS results
Roche immunoassay results!!!
Neurofiliment light, tau, proteomics
Big role for ADNI to provide samples for validation

5. LONG TERM PLANNING FOR ADNI
Will there or should there be an ADNI 4?
What happens if treatments are approved?
Role of ADNI in the treatment era?
Options for ADNI 4
Will new technologies be available?
Enrollment of new participants: Why?
New populations: younger participants?
Continuation of existing participants
Maintenance of data and sample repository

6. CONCLUSIONS ADNI 3 enrollment should be completed in one year
Major challenge are MCI, AD, and minority subjects
Validation of blood tests and longitudinal tau!!!
Need to start long term planning for ADNI:ADNI4